Answers are grounded in this paper and cite their sources.
Locally advanced rectal cancer is increasingly managed through prolonged neoadjuvant pathways, including total neoadjuvant therapy and, in selected patients, non-operative organ-preservation strategies. Although these approaches have improved opportunities for tumor response and organ preservation, they also extend the period during which nutritional decline, altered bowel function, fatigue, and loss of physiological reserve may occur. Nutritional vulnerability during this interval is heterogeneous and may not be adequately captured by body weight or body mass index alone. This state-of-the-art narrative review examines nutritional phenotypes relevant to patients with locally advanced rectal cancer during neoadjuvant therapy. It first outlines why this interval should be regarded as a period of dynamic nutritional vulnerability. It then summarizes key phenotypes that may inform risk stratification and care, including overt malnutrition, sarcopenia, sarcopenic obesity, myosteatosis, and treatment-related decline. Finally, it proposes a practical framework for phenotype-based assessment and targeted dietetic intervention prior to restaging and definitive management. Current evidence suggests that adverse body-composition change during neoadjuvant therapy may be associated with poorer treatment tolerance, inferior tumor response, and worse oncological outcomes. For dietitians, this supports a shift from one-off screening toward longitudinal assessment that integrates oral intake, symptom burden, body-composition risk, and treatment trajectory. Although intervention evidence remains heterogeneous, nutritional care during neoadjuvant therapy should be proactive, individualized, and embedded within modern rectal cancer pathways.
No takes yet. Share an insight, caveat, or question.
Gosavi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: